PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

nder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary).

Sheet 1 of 2

stitute for form 1449/PTO

SAN A TRACE

Complete if Known			
Application Number	10/077,406-Conf. #4141		
Filing Date	February 15, 2002		
First Named Inventor	Jeffrey L. BROWNING		
Art Unit	1646		
Examiner Name	E. B. O'Hara		
Attorney Docket Number	BGN-B191CPUSDV		

				U.S. PA	TENT DOCUMENTS	
Exam Initial	*	Cite No.1	Document Number Number-Kind Code ² (if Ianown)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/E	OH	A1"	US-5,082,783	01-21-1992	Emst et al.	
		A2	US 5,925,351	07-20-1999	Browning, et al.	
		A3	US 6,669,941	12-30-2003	Browning, et al.	
	1	A4	US 6,403,087	6-11-2002	Browning, et al.	
		A5	US 20020197254		Browning, et al.	
<u> </u>						
<u> </u>		<u> </u>				
L		L	<u> </u>	<u> </u>		1

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	۳٥
/EOH	B1*	WO-94/04679-A1	03-03-1994	Genentech, Inc.		
/EOH				Biogen, Inc., et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. 'Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, and/or country where published.		T²
/EOH	C1* /·	Androlewicz, Matthew J. et al., "Lymphotoxin is Expressed as a Heteromeric Complex with a Distinct 33-kDa Glycoprotein on the Surface of an Activated Human T Cell Hybridoma," J. of Biol. Chem., Vol. 267(4):2542-2547 (1992)	
	C2*	Arulanandam, Antonio R.N. et al., "A Soluble Multimeric Recombinant CD2 Protein Identifies CD48 as a Low Affinity Ligand for Human CD2: Divergence of CD2 Ligands during the Evolution of Humans and Mice," J. of Exp. Med., Vol. 177:1439-1450 (1993)	
	C3*	Baens, M. et al., "Construction and Evaluation of a hncDNA Library of Human 12p Transcribed Sequences Derived from a Somatic Cell Hybrid," Genomics, Vol. 16(1):214-218 (1993)	
	C4*	Browning, J.L. et al., "Lymphotoxin and an Associated 33-kDa Glycoprotein are Expressed on the Surface of an Activated Human T Cell Hybridoma," <i>J. of Immunol.</i> , Vol. 147(4):1230-1237 (1991)	
	C5*	Browning, J.L. et al., "Characterization of Surface Lymphotoxin Forms. Use of specific monoclonal antibodies and soluble receptors," <i>J. of Immunol.</i> , Vol. 154(1):33-46 (1995)	
	C6*	Browning, J.L. et al., "Lymphotoxin Beta, a Novel Member of the TNF Family That Forms a Heteromeric Complex with Lymphotoxin on the Cell Surface," Cell, Vol. 72(6):847-856 (1993)	
	C7*	Browning, J. et al., "Studies of the Differing Effects of Tumor Necrosis Factor and Lymphotoxin on the Growth of Several Human Tumor Lines," J. of Immunol., Vol. 143(6):1859-1867 (1989)	
	C8*	Cher, D.J. et al., "Two Types of Murine Helper T Cell Clone. II. Delayed-type hypersensitivity is mediated by TH1 clones," J. of Immunol., Vol. 138(11):3688-3694 (1987)	
V	C9.	Chisholm, P.L. et al., "Monoclonal antibodies to the integrin Alpha-4 subunit inhibit the murine contact hypersensitivity response," <i>Eur. J. Immunol.</i> , Vol. 23(3):682-688 (1993)	

Examiner /Cilean Ollians/	Date	02/44/2007
Signature /Eileen O'Hara/		03/14/2007
Signature / Lincoln C Hard/	Considered	00/ 1 // 2001

PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE espond to a collection of information unless it contains a valid OMB control number.

nder the Paperwork Reduction Act of 1995, no persons are required to

stitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

2

Sheet 2 · of

respond to a collection of the	ormation unless it contains a valid OMB control number.				
	Complete if Known				
Application Number	10/077,406-Conf. #4141				
Filing Date	February 15, 2002				
First Named Inventor	Jeffrey L. BROWNING				
Art Unit	1646				
Examiner Name	E. B. O'Hara				
Attorney Docket Number	BGN-B191CPUSDV				

/E0	OH/	C10*	Crowe et al., "Production of lymphotoxin (LT alpha) and a soluble dimeric form of its receptor using the baculovirus expression system," <i>J. Immunol. Methods</i> , Vol. 168(1):79-89 (1994)	
		C11*	Crowe, P.D. et al., "A Lymphotoxin-Beta Specific Receptor," Science, Vol. 264(5159):707-710 (1994)	
		C12*	Fägerstam et al., "Surface Plasmon Resonance Detection in Affinity Technologies: BlAcore," Handbook of Affinity Chromatography, Toni Kline, Editor, Vol. 63, pp. 229-252 (1993)	
		C13*	Huang, S. et al., "Immune Response in Mice that Lack the Interferon-gamma Receptor," Science, Vol. 259(5102):1742-1745 (1993)	
		C14*	Katz, J.D. et al., "T Helper Cell subsets In Insulin-Dependent Diabetes," Science, Vol. 268(5214):1185- 1188 (1995)	
		C15*	Lane, P. et al., "Activated human T Cells express a ligand for the human B cell-associated antigen CD40 which participates in T cell-dependent activation of B lymphocytes," Eur. J. Immunol., Vol. 22(10):2573-2578 (1992)	
		C16*	Lawton, P. et al., "Characterization of the Mouse Lymphotoxin-beta Gene," <i>J. of Immunol.</i> , Vol. 154(1):239-246 (1995)	
		C17*	Ling, L.E. et al., "Human Type I Interferon Receptor, IFNAR, Is a Heavily Glycosylated 120-130 kD Membrane Protein," J. Interferon and Cytokine Res., Vol. 15(1):55-61 (1995)	
		C18*	Morrissey, Philip J. et al., "CD4+ T Cells That Express High Levels of CD45RB Induce Wasting Disease When Transferred into Congenic Severe Combined Immunodeficient Mice. Disease Development Is Prevented by Cotransfer of Purified CD4+ T Cells," J. Exp. Med., Vol. 178:237-244 (1993)	
		C19*	Morrison, S.L. et al,. "In Vitro Antibodies: Strategies for Production and Application," <i>Ann. Rev. Immunol.</i> , Vol. 10:238-265 (1992)	
	·	C20*	Modlin, R.L. et al., "Type 2 cytokines and negative immune regulation in human infections," Current Opinion in Immunol., Vol. 5(4):511-517 (1993)	
		C21*	Powrie, F. et al., "Phenotypically distinct subsets of CD4+ T Cells Induce or Protect from Chronic Intestinal Inflammation in C. B-17 scid mice," International Immunology, Vol. 5(11):1461-1471 (1993)	
		C22*	Powrie, F. et al., "Inhibition of Th1 Responses Prevents Inflammatory Bowel Disease in scid Mice Reconstituted with CD45RBhi CD4+ T Cells," Immunity, Vol. 1(7):553-562 (1994)	
		C23*	Queen, Cary et al., "A humanized antibody that binds to the Interleukin 2 receptor," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , Vol. 86:10029-10033 (1989)	
		C24*	Reed, S.G. et al., "T-cell and cytokine responses in leishmaniasis," Current Opinion in Immunol., Vol. 5(4):524-531 (1993)	
		C25*	Renshaw, Blair R. et al., "Humoral Immune Responses in CD40 Ligand-deficient mice," <i>J. Exp. Med.</i> , Vol. 180:1889-1900 (1994)	
		C26*	Roitt et al., "Hypersensitivity - Type I-IV," Immunology, Mosby-Year Book Europe Ltd., 3rd ed., pp. 19.1-22.12 (1993)	
		C27*	Romagnani, S., "Lymphokine Production by Human T Cells in Disease States," Ann. Rev. Immunol., Vol. 12:227-257 (1994)	
		C28*	Sayegh, Mohamed H. et al., "CD28-B7 Blockade after Alloantigenic Challenge In Vivo Inhibits Th1 Cytokines by Spares Th2," <i>J. Exp. Med.</i> , Vol. 181:1869-1874 (1995)	
		C29*	Traunecker, A. et al., "Highly Efficient Neutralization of HIV with recombinant CD4-immunoglobulin molecules," <i>Nature</i> , Vol. 339(6219):68-70 (1989)	
		C30*	van Dullemen, H.M. et al., "Treatment of Crohn's Disease with Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2)," Gastroenterology, Vol. 109(1):129-135 (1995)	
		C31*	Ware, C.F. et al., "The Ligands and Receptors of the Lymphotoxin System," Current Topics Microbiol. Immunol., Vol. 198:175-218 (1995)	
1	/	C32*	Zhou, M. et al., "Real-Time Measurements of Kinetics of EGF Binding to Soluble EGF Receptor Monomers and Dimers Support the Dimerization Model for Receptor Activation," <i>Biochemistry</i> , Vol. 32(32):8193-8198 (1993)	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Eileen O'Hara/	Date	03/14/2007
[Oignaturo]	72110011 O Hala/	Considered	03/14/2001